Publicaciones en las que colabora con MANUEL EDUARDO MUÑOZ TORRES (21)

2023

  1. Analysis of the Genetic Relationship between Atherosclerosis and Non-Alcoholic Fatty Liver Disease through Biological Interaction Networks

    International Journal of Molecular Sciences, Vol. 24, Núm. 4

  2. Cardioprotective function of sclerostin by reducing calcium deposition, proliferation, and apoptosis in human vascular smooth muscle cells

    Cardiovascular Diabetology, Vol. 22, Núm. 1

  3. Systemic effects of hypophosphatasia characterization of two novel variants in the ALPL gene

    Frontiers in Endocrinology, Vol. 14

2022

  1. Characterization of Genetic Variants of Uncertain Significance for the ALPL Gene in Patients With Adult Hypophosphatasia

    Frontiers in Endocrinology, Vol. 13

  2. Exploring the Role of Sclerostin as a Biomarker of Cardiovascular Disease and Mortality: A Scoping Review

    International Journal of Environmental Research and Public Health, Vol. 19, Núm. 23

  3. Identification of Potential Targets Linked to the Cardiovascular/Alzheimer’s Axis through Bioinformatics Approaches

    Biomedicines, Vol. 10, Núm. 2

  4. The Contribution of Wnt Signaling to Vascular Complications in Type 2 Diabetes Mellitus

    International Journal of Molecular Sciences, Vol. 23, Núm. 13

2011

  1. A nutritional intervention study with hydrolyzed collagen in pre-pubertal Spanish children: Influence on bone modeling biomarkers

    Journal of Pediatric Endocrinology and Metabolism, Vol. 24, Núm. 3-4, pp. 147-153

2009

  1. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate

    Maturitas, Vol. 64, Núm. 3, pp. 188-192

2008

  1. Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis

    Journal of Endocrinological Investigation, Vol. 31, Núm. 5, pp. 416-421

2006

  1. Catepsina K y resorción ósea: efecto del tratamiento con alendronato en mujeres con osteoporosis postmenopáusica

    Actualidad médica, Vol. 92, Núm. 773, pp. 99-105

2005

  1. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women

    Osteoporosis International, Vol. 16, Núm. 11, pp. 1368-1374

2004

  1. Susceptibility for postmenopausal osteoporosis: Interaction between genetic, hormonal and lifestyle factors

    Calcified Tissue International, Vol. 75, Núm. 5, pp. 373-379

1995

  1. Ketoconazole therapy: Hormonal and clinical effects in non-tumoral hyperandrogenism

    Obstetrical and Gynecological Survey, Vol. 50, Núm. 1, pp. 42-44

1994

  1. Hyperinsulinemia in polycystic ovary syndrome: relationship to clinical and hormonal factors

    The Clinical Investigator, Vol. 72, Núm. 11, pp. 853-857

  2. Ketoconazole therapy: Hormonal and clinical effects in non-tumoral hyperandrogenism

    European Journal of Endocrinology, Vol. 130, Núm. 4, pp. 333-338

  3. Reduction of endogenous, ovarian and adrenal androgens with ketoconazole does not alter insulin response in the polycystic ovary syndrome

    Journal of Endocrinological Investigation, Vol. 17, Núm. 8, pp. 647-652

1993

  1. PERFIL LIPIDICO DE LA PACIENTE HIPERANDROGENICA EN TRATAMIENTO CON KETOCONAZOL Y SU RELACION CON LA EVOLUCION DEL PATRON HORMONAL

    Medicina Clinica, Vol. 101, Núm. 20, pp. 766-768

1992

  1. Dehydroepiandrosterone sulfate and other possible influencing factors that modulate sex hormone-binding globulin levels in the hirsute patient

    Journal of Steroid Biochemistry and Molecular Biology, Vol. 42, Núm. 6, pp. 607-611

1990

  1. Muestreo venoso selectivo intraoperatorio (MVSI) en el hiperparatiroidismo primario (resumen)

    Actualidad médica, Tomo 76, Núm. 710, pp. 180-189